PolyPeptide Group AG (SWX: PPGN)

Market Cap	1.09B
Revenue (ttm)	311.55M
Net Income (ttm)	-27.50M
Shares Out	32.98M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,708
Open	32.60
Previous Close	33.05
Day's Range	31.80 - 32.65
52-Week Range	14.11 - 35.80
Beta	1.13
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 11, 2025

About PolyPeptide Group AG

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorde...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,277
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2023, ISN's revenue was 172.05 million, a decrease of -26.08% compared to the previous year's 232.75 million. Earnings were 82.50 million, a decrease of -43.28%.

Financial numbers in EUR